Uremia alters HDL composition and function.

Functional impairment of HDL may contribute to the excess cardiovascular mortality experienced by patients with renal disease, but the effect of advanced renal disease on the composition and function of HDL is not well understood. Here, we used mass spectrometry and biochemical analyses to study alterations in the proteome and lipid composition of HDL isolated from patients on maintenance hemodialysis. We identified a significant increase in the amount of acute phase protein serum amyloid A1, albumin, lipoprotein-associated phospholipase A2, and apoC-III composing uremic HDL. Furthermore, uremic HDL contained reduced phospholipid and increased triglyceride and lysophospholipid. With regard to function, these changes impaired the ability of uremic HDL to promote cholesterol efflux from macrophages. In summary, the altered composition of HDL in renal disease seems to inhibit its cardioprotective properties. Assessing HDL composition and function in renal disease may help identify patients at increased risk for cardiovascular disease.

[1]  P. Stiegler,et al.  Protein carbamylation renders high-density lipoprotein dysfunctional. , 2011, Antioxidants & redox signaling.

[2]  A. Vaughan,et al.  ATP binding cassette G1-dependent cholesterol efflux during inflammation1 , 2011, Journal of Lipid Research.

[3]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[4]  P. Stenvinkel,et al.  Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease , 2010, Journal of internal medicine.

[5]  M. Phillips,et al.  High-density lipoprotein heterogeneity and function in reverse cholesterol transport , 2010, Current opinion in lipidology.

[6]  N. Vaziri,et al.  HDL metabolism and activity in chronic kidney disease , 2010, Nature Reviews Nephrology.

[7]  J. Danesh,et al.  Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.

[8]  P. Giral,et al.  Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[9]  H. Moradi,et al.  In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. , 2009, Kidney international.

[10]  D. Rader,et al.  Update on strategies to increase HDL quantity and function , 2009, Nature Reviews Cardiology.

[11]  A. Kontush,et al.  Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[12]  H. Scharnagl,et al.  Plasma-Advanced Oxidation Protein Products Are Potent High-Density Lipoprotein Receptor Antagonists In Vivo , 2009, Circulation research.

[13]  Muredach P. Reilly,et al.  Inflammation Impairs Reverse Cholesterol Transport In Vivo , 2009, Circulation.

[14]  A. Vaughan,et al.  Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux* , 2009, Journal of Lipid Research.

[15]  N. Webb,et al.  HDL Remodeling During the Acute Phase Response , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[16]  A. Bobik Apolipoprotein CIII and atherosclerosis: beyond effects on lipid metabolism. , 2008, Circulation.

[17]  A. Jurek,et al.  The ability of HDL to inhibit VCAM-1 expression and oxidized LDL uptake is impaired in renal patients. , 2008, Clinical biochemistry.

[18]  G. Watts,et al.  Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. , 2008, Clinical science.

[19]  D. Sviridov,et al.  Antiatherogenic functionality of high density lipoprotein: how much versus how good. , 2008, Journal of atherosclerosis and thrombosis.

[20]  A. Tall,et al.  Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.

[21]  K. Kalantar-Zadeh,et al.  HDL-inflammatory index correlates with poor outcome in hemodialysis patients. , 2007, Kidney international.

[22]  H. Ginsberg,et al.  Lipoprotein metabolism in chronic renal insufficiency , 2007, Pediatric Nephrology.

[23]  Sina A. Gharib,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[24]  J. Raynes,et al.  The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. , 2007, The Biochemical journal.

[25]  K. Siamopoulos,et al.  PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  K. Resing,et al.  Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.

[27]  A. Zalewski,et al.  Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Per Leanderson,et al.  Lipoproteomics II: Mapping of proteins in high‐density lipoprotein using two‐dimensional gel electrophoresis and mass spectrometry , 2005, Proteomics.

[29]  P. Linsel-Nitschke,et al.  HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.

[30]  R. Heller,et al.  2-Chlorohexadecanal Derived From Hypochlorite-Modified High-Density Lipoprotein–Associated Plasmalogen Is a Natural Inhibitor of Endothelial Nitric Oxide Biosynthesis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004, Circulation research.

[32]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[33]  John R Yates,et al.  Reproducibility of quantitative proteomic analyses of complex biological mixtures by multidimensional protein identification technology. , 2003, Analytical chemistry.

[34]  M. Adachi,et al.  Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. , 2003, Kidney international.

[35]  P. Stenvinkel Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. , 2003, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[36]  Peter Stenvinkel,et al.  The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.

[37]  S. Lestavel,et al.  Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[38]  L. Havekes,et al.  Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[39]  R. Krauss,et al.  Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility. , 1999, Biochimica et biophysica acta.

[40]  Y. Marcel,et al.  Specific Phospholipid Association with Apolipoprotein A-I Stimulates Cholesterol Efflux from Human Fibroblasts , 1996, The Journal of Biological Chemistry.

[41]  A. von Eckardstein,et al.  Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. , 1991, The Journal of clinical investigation.

[42]  G. Coetzee,et al.  Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. , 1986, The Journal of biological chemistry.

[43]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[44]  G. Kaysen Lipid and lipoprotein metabolism in chronic kidney disease. , 2009, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[45]  Rebekah L. Gundry,et al.  Investigation of an albumin‐enriched fraction of human serum and its albuminome , 2007, Proteomics. Clinical applications.

[46]  Farhad Rezaee,et al.  Proteomic analysis of high‐density lipoprotein , 2006, Proteomics.